Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Erik Lundgren
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Beta
- 1.48
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -7.68
Financials
Net Income
$-42.31MEBITDA
$-42.27MFree Cash Flow
$-28.49MEPS (diluted)
$-0.99Shares Outstanding (diluted)
42.80M+5235.7%Operating Expenses
$43.37MCash & Debt
$131.96MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-97.17M | $-6.24 |
| 2024 | $0.00 | $-100.51M | $-10.03 |
| 2023 | $0.00 | $-93.61M | $-21.12 |
| 2022 | $0.00 | $-120.41M | $-37.84 |
| 2021 | $0.00 | $-92.94M | $-39.30 |
| 2020 | $0.00 | $-44.02M | $-28.10 |
| 2019 | $0.00 | $-34.83M | $-45.24 |
| 2018 | $0.00 | $-41.48M | $-136.28 |
| 2017 | $0.00 | $-52.08M | $-524.00 |
| 2016 | $6.3K | $-40.97M | $-524.00 |
| 2015 | $0.00 | $-52.02M | $-828.00 |
| 2014 | $0.00 | $-47.67M | $-1416.00 |
| 2013 | $0.00 | $-32.72M | $-528.14 |
| 2012 | $0.00 | $-6.70M | $-128.50 |
Valuation
IMUXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (17)
- Newsprnewswire.com·9d ago·Neutral
…ief Data and Digital Officer and Chief People Officer to Support Regulatory and Commercial Readiness – NEW YORK, Nov. 13, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. "As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) …
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results Immunic NASDAQ: IMUX is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in progressive disease, with the first patients expected to enroll in the first half of 2027.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Immunic to Participate in Investor Conferences in November NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November: November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference. Erik Lundgren, Chief Executive Officer, and Jason Tardio, President and Chief Operating Officer, will partici…
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET. In addition to members of Immunic's management team, including…
View source ↗ - Newsprnewswire.com·32d ago·Negative
…Measure Suggests Overall Benefit of Vidofludimus Calcium in Progressive Multiple Sclerosis Patients – NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that new clinical, biomarker, and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), are being presented across four pos…
View source ↗ - Newsproactiveinvestors.com·34d ago·Neutral
Immunic adds new Chief People Officer ahead of Phase 3 readout Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Jaa Roberson as its first Chief People Officer, adding a senior human resources leader as the biotechnology company prepares for a pivotal multiple sclerosis trial readout expected by the end of 2026. Roberson will report to CEO Erik Lundgren and join the executive leadership team.
View source ↗ - Newsprnewswire.com·34d ago·Neutral
…ltiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company – NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive l…
View source ↗ - Newsproactiveinvestors.com·46d ago·Negative
Immunic to present four vidofludimus calcium abstracts at MSToronto2026 Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus calcium, have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21 to 23. The oral therapy is a Nurr1 activator under development for neurologic diseases.
View source ↗ - Newsprnewswire.com·46d ago·Positive
…fludimus Calcium Treatment Maintained Through Extension Week 48, With Low Treatment Discontinuation – NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that four abstracts highlighting new clinical, biomarker and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), have bee…
View source ↗ - Newsproactiveinvestors.com·81d ago·Neutral
Immunic to host virtual relapsing MS R&D Day on September 9 Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president…
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.
View source ↗ - Newsprnewswire.com·82d ago·Neutral
… Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.
View source ↗ - Newsseekingalpha.com·89d ago·Neutral
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.
View source ↗ - Newsproactiveinvestors.com·103d ago·Negative
Immunic advances MS drug toward key Phase 3 data, expects results by year-end Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2
View source ↗ - Newsprnewswire.com·103d ago·Neutral
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 T
View source ↗ - Newsprnewswire.com·104d ago·Neutral
Immunic Appoints Elena Ridloff to Board of Directors – Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today annou
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.82 per share
Typical surprise -26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.99 vs $-0.79miss
- Tue, Aug 11$-0.80 vs $-1.16beat
- Wed, May 13$-1.08 vs $-0.71miss
- Thu, Feb 26$-1.20 vs $-0.90miss
- Thu, Nov 13$-1.30 vs $-0.18miss
- Thu, Aug 7$-2.00 vs $-1.58miss
Estimates and results for IMUX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMUX officers and directors.
- Bought
- $347k
- Sold
- —
8 trades
0 trades
- Nash Duanebought
- Tardio Jasonbought
- Neermann Joergbought
- Vitt Danielbought
- Neermann Joergbought
- Whaley Glennbought
- Rudick Richard Alanbought
- Rudick Richard Alanbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMUX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
